Page 3,255«..1020..3,2543,2553,2563,257..3,2603,270..»

Category Archives: Transhuman News

Hacking the Cancer Genome

Posted: September 24, 2014 at 4:43 pm

These days, cancer is as much a target for researchers with number-crunching skills and their data-mining tools as it is for scientists in biomedical research labs. And one potentially powerful big-data approach to conquering cancerwhich involves discovering clever genetic tricks to make cancer cells kill themselveshas moved in a promising new direction this month.

Scottish, Israeli, and American researchers have reported a new discovery that analyzes existing cancer gene databases for clues to combinations of genes that together can kill tumor cells while leaving healthy cells untouched. The idea takes advantage of a phenomenon called synthetic lethality, which in oncology was first explored 17 years ago as a potentially fruitful new line of cancer treatment.

One of the new papers coauthors, Eytan Ruppin, director of the University of Marylands Center for Bioinformatics and Computational Biology, says cancer cells are like regular cells run amok. They, like regular cells, typically have some 10,000 genes. But in cancer cells, many more of these genes are inactivemeaning that for whatever reasons, those genes dont produce the proteins that a healthy version of the cell would be producing.

Since the 1920s, its been observed that all cells in fact have networks of secret self-destruct switches: When both of a key pair of genes become inactive, the entire cell begins the process of shutdown and cell death.

So, Ruppin says, the hurdle that needs to be overcome in order to make this possible broad-spectrum genetic cancer treatment work is discovering and cataloging as many of these secret synthetically lethal (SL) gene pair combinations as nature has provided. Then, when a patients cancer is biopsied, and its genome is taken, an oncologist can look to see which genes in the patients cancer cells are inactive.

For example, say that the oncologist discovers in an SL database that an inactive gene in a patients tumor (call it Gene A) happens to have a corresponding synthetically lethal partner gene (call it Gene B).

In this case, then, a drug that inactivates Gene B will trigger the cell death process in the tumor but not in the persons healthy cells. (Depending on what Gene B does, there might also be side effects from switching Gene B off. But so long as Gene A remains active throughout the rest of the persons body, those side-effects should not include cell death.)

Ruppin and his collaborators used a clever data mining technique to discover more than a thousand candidate SL gene combinations. They plumbed the U.S. National Cancer Institutes Cancer Genome Atlas, which itself contains thousands of genomes of different biopsied tumor samples.

They then ran searches for various inactive genes. So, for the sake of example, say they found some of the cancers in the database with Gene X inactivated. And some of the cancers in the database had Gene Y inactivated. If Genes X and Y dont form an SL pair, there should then be plenty of examples in the database of cancers where both X and Y were inactive. However, if Genes X and Y do form an SL pair, then there should be almost no examples of tumors in the database where those two genes are both inactive.

You would have expected them to be inactive together at a certain rate, given their individual inactive frequencies, Ruppin says. But when you look at the data, you find that they are never inactive together, Ruppin adds that this, is a very strong indication that they are synthetically lethal. Because whenever they were inactive together, they were actually eliminated from the population. Because these cells died.

Continued here:
Hacking the Cancer Genome

Posted in Genome | Comments Off on Hacking the Cancer Genome

Clues to superbug evolution: Microbiologists sequence entire genome of a Klebsiella pneumoniae strain

Posted: at 4:43 pm

Imagine going to the hospital with one disease and coming home with something much worse, or not coming home at all.

With the emergence and spread of antibiotic-resistance pathogens, healthcare-associated infections have become a serious threat. On any given day about one in 25 hospital patients has at least one such infection and as many as one in nine die as a result, according to the Centers for Disease Control and Prevention.

Consider Klebsiella pneumoniae, not typically a ferocious pathogen, but now armed with resistance to virtually all antibiotics in current clinical use. It is the most common species of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. As carbapenems are considered the antibiotic of last resort, CREs are a triple threat for their resistance to nearly all antibiotics, high mortality rates and ability to spread their resistance to other bacteria.

But there is hope. A team of Sandia National Laboratories microbiologists for the first time recently sequenced the entire genome of a Klebsiella pneumoniae strain, encoding New Delhi Metallo-beta-lactamase (NDM-1). They presented their findings in a paper published in PLOS One, "Resistance Determinants and Mobile Genetic Elements of an NDM-1 Encoding Klebsiella pneumoniae Strain."

The Sandia team of Corey Hudson, Zach Bent, Robert Meagher and Kelly Williams is beginning to understand the bacteria's multifaceted mechanisms for resistance. To do this, they developed several new bioinformatics tools for identifying mechanisms of genetic movement, tools that also might be effective at detecting bioengineering.

"Once we had the entire genome sequenced, it was a real eye opener to see the concentration of so many antibiotic resistant genes and so many different mechanisms for accumulating them," explained Williams, a bioinformaticist. "Just sequencing this genome unlocked a vault of information about how genes move between bacteria and how DNA moves within the chromosome."

Meagher first worked last year with Klebsiella pneumoniae ATCC BAA-2146 (Kpn2146), the first U.S. isolate found to encode NDM-1. Along with E.coli, it was used to test an automatic sequencing library preparation platform for the RapTOR Grand Challenge, a Sandia project that developed techniques to allow discovery of pathogens in clinical samples.

"I've been interested in multi-drug-resistant organisms for some time. The NDM-1 drug resistance trait is spreading rapidly worldwide, so there is a great need for diagnostic tools," said Meagher. "This particular strain of Klebsiella pneumoniae is fascinating and terrifying because it's resistant to practically everything. Some of that you can explain on the basis on NDM-1, but it's also resistant to other classes of antibiotics that NDM-1 has no bearing on."

Unlocking Klebsiella pneumoniae

Assembling an entire genome is like putting together a puzzle. Klebsiella pneumoniae turned out to have one large chromosome and four plasmids, small DNA molecules physically separate from and able to replicate independently of the bacterial cell's chromosomal DNA. Plasmids often carry antibiotic resistant genes and other defense mechanisms.

Go here to see the original:
Clues to superbug evolution: Microbiologists sequence entire genome of a Klebsiella pneumoniae strain

Posted in Genome | Comments Off on Clues to superbug evolution: Microbiologists sequence entire genome of a Klebsiella pneumoniae strain

$1 million Palo Alto Longevity "Fountain of Youth" Prize – Regenerative Processing Plant Accepts the Challenge!

Posted: at 4:43 pm

PALM HARBOR, Fla., Sept. 24, 2014 /PRNewswire/ --The Palo Alto Longevity Prize is a $1 million life science competition that challenges teams from all over the world to extend life spans. For more information log on to http://www.PaloAltoPrize.com. Regenerative Processing Plant, LLC (RPP) has accepted this ambitious challenge and has registered their intent to participate.

In a recent study, Harvard scientists found a protein that could reverse the aging process; May 2014, the Harvard Stem Cell Institute showed injections of a growth factor called Growth Differentiation Factor 11 (GDF-11) appears to have special regenerative properties. Many tissues, including damaged muscle, were shown to regenerate in the study. Thus, GDF-11 is being called the "Youth Hormone".

Regenerative Processing Plant's (RPP) First Sterile Product: PDA Human Amniotic Fluid is also the first product on the market to Lot test for the presence of GDF-11.

Dr. C. Randall Harrell, RPP'S CEO and Medical Director comments that:

"GDF-11 is an exciting discovery for Regenerative Medicine. We are proud to have the first Amniotic Fluid product on the market to recognize the regenerative healing potential of GDF-11."

He expressed enthusiasm about the upcoming product launch, stating:

"RPP was established to help bring the science of the body's natural ability to heal itself to the practice of medicine using safe and effective products. RPP intensely focuses on the science of regenerative healing with a world class team of scientists."

RPP's products are available to the healthcare community now for the treatment of Plastic Surgery, Wound Healing, Sports Medicine, Pain Management, Orthopedics, Spinal Therapies and other Regenerative Medicine Therapies through their personal physician. Dr. Harrell also notes:

"For years, professional athletes and wealthy individuals have traveled around the world seeking similar treatments to expedite repair and healing of injuries and degenerative diseases. Now everyone can have access to the same opportunities right here at home, collected and manufactured in the USA."

RPP has several additional products in R&D and will continue to focus on their Proprietary Patented PDA Sterile Process and placental derived amnion products. To learn more about RPP's products, please contact Raquel Roque, 800-781-0818.

Continued here:
$1 million Palo Alto Longevity "Fountain of Youth" Prize - Regenerative Processing Plant Accepts the Challenge!

Posted in Human Longevity | Comments Off on $1 million Palo Alto Longevity "Fountain of Youth" Prize – Regenerative Processing Plant Accepts the Challenge!

Unrefined Shea Butter-Best For Eczema – Video

Posted: at 4:43 pm


Unrefined Shea Butter-Best For Eczema
http://amzn.to/1uLmDWE Unrefined Shea Butter is best used for most skin care conditions: Acne , Eczema, Psoraises, Dry skin, Strech Marks, Rashes, Sunburn, Hair scalp and many more. It is used...

By: eternal Beauty

Here is the original post:
Unrefined Shea Butter-Best For Eczema - Video

Posted in Eczema | Comments Off on Unrefined Shea Butter-Best For Eczema – Video

Guttate Psoriasis Treatment- Dermasis Review – Video

Posted: at 4:42 pm


Guttate Psoriasis Treatment- Dermasis Review
http://bit.ly/1rgQGqr Click the Link above to receive your FREE package of Dermasis. Guttate Psoriasis psoriasis psoriasis treatment psoriasis diet psoriasis...

By: Wayne Posey

Read more:
Guttate Psoriasis Treatment- Dermasis Review - Video

Posted in Psoriasis | Comments Off on Guttate Psoriasis Treatment- Dermasis Review – Video

Stem Cell Treatment For Psoriasis – Video

Posted: at 4:42 pm


Stem Cell Treatment For Psoriasis
http://bit.ly/1tPneYK Click here to find out how to treat psoriasis for good in less than one week. It #39;s simple and effective and really is effective! Stem c...

By: Kasie Isbell

View original post here:
Stem Cell Treatment For Psoriasis - Video

Posted in Psoriasis | Comments Off on Stem Cell Treatment For Psoriasis – Video

Psoriasis Testimonios con Nopsor – Video

Posted: at 4:42 pm


Psoriasis Testimonios con Nopsor
Psoriasis testimonios de Alivio con Nopsor.

By: nopsoriasis

More here:
Psoriasis Testimonios con Nopsor - Video

Posted in Psoriasis | Comments Off on Psoriasis Testimonios con Nopsor – Video

Celgene Wins U.S. Approval of New Psoriasis Pill

Posted: at 4:42 pm

Celgene Corp. (CELG) won U.S. approval for its drug to treat the skin disease psoriasis, a medicine that will compete with injections that now generate billions of dollars in sales each year.

The Food and Drug Administration cleared Otezla for people with moderate to severe psoriasis, Celgene said today in a statement. Psoriasis is the most common autoimmune disease in the U.S., affecting 7.5 million Americans, according to the National Psoriasis Foundation. The agency in March authorized the treatment, also known as apremilast, to combat a related condition.

Psoriasis causes raised, red, scaly patches on the skin. Its commonly treated with injections, including AbbVie Inc. (ABBV)s Humira, and Enbrel from Amgen Inc. (AMGN) and Pfizer Inc. (PFE) Otezla is expected to generate $1.03 billion in sales in 2017, according to the average of 11 analysts estimates compiled by Bloomberg.

Otezla offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments, M. Shane Chapman, section chief of dermatology at Dartmouth-Hitchcock Medical Center, said in the statement. Because the product labeling does not require routine laboratory monitoring, oral Otezla may be a welcome new option for patients and physicians looking for a different treatment experience.

Celgene, the Summit, New Jersey-based maker of the cancer drug Revlimid, rose 1 percent to $93.12 at the close in New York. The companys shares have gained 27 percent in the past 12 months.

The FDA approved Otezla this year to treat psoriatic arthritis, which causes painful, stiff and swollen joints and occurs in about 30 percent of people who suffer from psoriasis. The drug is associated with an increased risk of depression. Common side effects include diarrhea, headache and nausea.

Celgene is studying Otezla for use against other diseases as well, including rheumatoid arthritis and another form of arthritis that can lead to a new bone formation on the spine, called ankylosing spondylitis. The company said in June the drug failed to significantly help patients in a trial with ankylosing spondylitis.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Drew Armstrong, Andrew Pollack

Press spacebar to pause and continue. Press esc to stop.

Original post:
Celgene Wins U.S. Approval of New Psoriasis Pill

Posted in Psoriasis | Comments Off on Celgene Wins U.S. Approval of New Psoriasis Pill

Nurse Hollie McEwen hanged herself after becoming tormented by chronic psoriasis

Posted: at 4:42 pm

Hollie McEwen fell into depression after suffering from severe psoriasis The 'beautiful, vibrant' 28-year-old had first class honours degree in nursing She was found hanged after she became tormented by the skin condition Inquest heard skin condition played a 'large part' in what she decided to do Medical professionals had prescribed her drugs to help combat depression

By Corey Charlton for MailOnline

Published: 05:08 EST, 24 September 2014 | Updated: 12:06 EST, 24 September 2014

976 shares

166

View comments

A health visitor with a first class honours degree in nursing was found hanged after she became tormented by her severe skin condition.

Hollie McEwen, a dedicated professional, first suffered psoriasis as a 12-month-old but it eased with treatment.

However, it later reappeared due to stress and the 28-year-old became so depressed she took her own life at home.

Her father Andrew told an inquest: 'Her condition played a large part in what she decided to do.

Original post:
Nurse Hollie McEwen hanged herself after becoming tormented by chronic psoriasis

Posted in Psoriasis | Comments Off on Nurse Hollie McEwen hanged herself after becoming tormented by chronic psoriasis

EmTech: Risks of Gene-Editing Drugs Need Study, Pioneer Says

Posted: at 4:42 pm

One of the inventors of gene editing says scientists should proceed cautiously before testing it in people.

Feng Zhang

Citing the risk of deadly mistakes, a leading researcher speaking at MIT Technology ReviewsEmTech conferenceon Tuesday said the risks of gene editing need to be better understood before the technology can be used in medical studies.

Feng Zhang, a researcher at MIT, helped invent a powerful new way to alter DNA that he compared in his talk to a search-and-replace function for the genome.

Several startups have already sprung up to turn the technology into new kinds of gene-therapy drugs, including CRISPR Therapeutics and Editas Medicine, a biotechnology company that Zhang cofounded last year with venture capitalists who invested $43 million.

These companies hope to correct diseases, like cystic fibrosis, caused by faulty DNA. In other cases, Zhang said, changing a persons DNA could provide a protective effectfor instance, conferring immunity to HIV.

The concept is very powerful, but to make any correction in the body is very challenging, he said.

Looming over researchers is the 1999 death of Jesse Gelsinger, a volunteer in an early gene therapy study in Pennsylvania. That failure dealt a huge setback to genetic drugs. Later it was shown that such treatments, even when they work, could sometimes cause cancer by making unwanted changes to a persons genome.

One of the early lessons from gene therapy is to go slowly, said Zhang. The lesson is that we need to understand a system carefully before putting it into a person.

Gradually, however, gene therapy has staged a comeback. In 2012, a treatment called Glybera was the first to be approved in Europe. Its not yet for sale in the U.S., but numerous gene treatments are being tested in patients.

See the article here:
EmTech: Risks of Gene-Editing Drugs Need Study, Pioneer Says

Posted in Gene Medicine | Comments Off on EmTech: Risks of Gene-Editing Drugs Need Study, Pioneer Says

Page 3,255«..1020..3,2543,2553,2563,257..3,2603,270..»